



Fondazione
Epatocentro Ticino

Scientific Programme

Day 1 - November 20

| | |
|---------------|--|
| 8:50-9:00 | Welcome and Introduction <i>Andreas Cerny, Switzerland</i> <i>Benedetta Terzioli Beretta-Piccoli, Switzerland</i> <i>Mario Bianchetti, Switzerland</i> |
| <hr/> | |
| 9:00-10:30 | Session 1 Chairs: <i>Andreas Cerny, Switzerland</i> <i>Giorgina Mieli-Vergani, UK</i> |
| 9.00 – 9.20 | Genetics in primary biliary cholangitis beyond GWAS <i>Pietro Invernizzi, Italy</i> |
| 9.20 – 09.40 | Therapeutic developments in autoimmune liver diseases <i>Tom Hemming Karlsen, Norway</i> |
| 09.40 – 10.00 | There is more than one cause for primary sclerosing cholangitis <i>Richard Thompson, UK</i> |
| 10.00 – 10.30 | 30' Panel discussion and Q&A |
| <hr/> | |
| 10:30-10:45 | BREAK |
| <hr/> | |

October – November 2020

<https://www.swissautoimmuneliver.ch/>

For more information, please contact : swissaldmeeting@epatocentro.ch



Fondazione
Epatocentro Ticino

10:45 – 12.15 Session 2

Chairs:

Florian Bihl

Diego Vergani

10.45 – 11.05 Autoimmune hepatitis type 2
Giorgina Mieli-Vergani, UK

11.05 – 11.25 Autoantibodies in autoimmune liver diseases: clinical aspects
Luigi Muratori, Italy

11.25 – 11.45 Beyond guidelines
Michael Manns, Germany

11.45 – 12.15 30' Panel discussion and Q&A

14.00 – 15:50 Session 3

Chairs:

Michael Manns, Germany

Pietro Majno-Hurst, Switzerland

14.00 – 14.20 Living in the Liver, overcoming constraints on T cells
Mala Maini, UK

14:20-14:40 Anti-tumor autologous T-cell therapy for HBV-associated
hepatocellular carcinoma
Antonio Bertoletti, Singapore

14:40 – 15:00 Animal model of autoimmune liver diseases
Urs Christen, Germany

15.00 – 15.20 The impact of gut microbiome on T-cell trafficking
Giandomenica Iezzi, Switzerland

15.20 – 15.50 30' Panel discussion and Q&A

October – November 2020

<https://www.swissautoimmuneliver.ch/>

For more information, please contact : swissaldmeeting@epatocentro.ch



Fondazione
Epatocentro Ticino

Day 2 November 21

9:00-10:20 **Session 4**

Chairs:

Andrea De Gottardi, Switzerland

Maria Isabel Lucena, Switzerland

9.00 – 9.20 Immunometabolic drugs

Michael Trauner, Austria

9.20 – 09.40 Drug-induced liver injury and autoimmunity

Raul Andrade, Spain

9.40 – 10.00 Post-transplant autoimmune liver diseases

Diego Vergani, UK

10.00 – 10.20 Gut-liver axis

Antonio Moschetta, Italy

10:20-10:40 BREAK

10:40 – 11:15 **Oral session**

Chairs:

Michael Trauner

Andreas Cerny

10:40 – 10:50 Antibody-mediated clearance of serum HBsAg has minimal impact on CD8+ T cell responses in mouse models of HBV pathogenesis

Valeria Fumagalli, Italy

October – November 2020

<https://www.swissautoimmuneliver.ch/>

For more information, please contact : swissaildmeeting@epatocentro.ch



Fondazione
Epatocentro Ticino

- 10:50 – 11.00 Cell specific transcriptomic analyses reveals a disassociation between treatment response and peripheral markers of immune activation in primary biliary cholangitis
Victoria Mulcahy, UK
- 11.00 – 11.10 Gamma-glutamyl transferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase
Alessio Gerussi, Italy
- 11.10 – 11.20 The PBC Foundation App: What Have We Learned and What Should We Do Next?
Robert Mitchell-Thain, UK
- 11.20 – 11.50 30' Panel discussion and Q&A
- 11.50 – 12.00 What have we learned and what should we do next
Pietro Invernizzi, Italy
- 12.00 – 12.15 Concluding remarks
Andreas Cerny, Switzerland
Donna Cryer, President & CEO - The Global Liver Institute, USA
Benedetta Terzioli Beretta-Piccoli, Switzerland

October – November 2020

<https://www.swissautoimmuneliver.ch/>

For more information, please contact : swissaldmeeting@epatocentro.ch